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Summary The MC-2 fibrosarcoma, which is a transplantable tumour syngeneic for BALB/c mice,
metastasizes to lymph nodes draining subcutaneous inoculation sites, and also to the lungs. T cell-mediated
immunity was detected in Winn assays using spleens from excision immunized mice. T cell-mediated anti-
tumour immunity was also detected in spleens from mice with small tumours but disappeared as the tumour
burden increased. Protective immune spleen cell activity in the Winn assay was inhibited by prior addition of
spleen cells from mice with large tumours, causing increased tumour incidence. Splenic metastases
occasionally occurred in the MC-2 model, but were not demonstrable by bioassay in any of the experiments
detecting splenic suppressor cell activity. In vivo protective activity was restored to advanced-stage tumour-
bearer spleens by whole-body ionizing irradiation (0.5 and 2.5Gy) of donor mice 15 h before sampling. Spleen
cells from mice with small tumours remained protective after 1.5, 2.5 and 4.0Gy of irradiation in vivo. These
results are consistent with the properties of radiosensitive suppressor T cells. In contrast to reports in other
tumour models, suppressor cells were not detected until late in the course of MC-2 development. This is
surprising in view of the aggressively metastatic nature of MC-2. It is postulated that modulation of the anti-
tumour immune response by the suppressor cells is associated with metastasis in this tumour model. The late
appearance of both suppressor cells and metastatic cells in the spleen may reflect similar processes occurring
earlier in regional lymph nodes.
The metastasis of malignant neoplasms is the major
clinical problem in the treatment of cancer. More
than 50% of cancer patients have metastases by the
time their disease is detected (DeVita et al., 1975).
Of deaths directly attributable to the tumour
burden in cancer victims, the majority are caused
by metastases rather than the primary tumour
(Roos & Dingemans, 1979).
Metastasis is a multifactoral process in which
both intrinsic (tumour) and extrinsic (host) factors
contribute (Roos & Dingemans, 1979). Survival of
tumour cells after invasion of tissue is at least
partially under immunological control. The level of
lymphoreticular infiltration into primary tumours
has been inversely correlated with metastasis in
some animal models (Eccles & Alexander, 1974)
and human disease (Hamlin, 1968). This relationship
is, however, not universally detected (Talmadge et
al., 1981). Antitumour activity detected in lymph
nodes draining primary tumours is often lost as
tumour size increases (Flannery et al., 1973).
There would appear to be a link between
systemic immunity manifested as concomitant
tumour immunity (CTI) and metastasis (Gershon,
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1974). CTI cannot be induced by all tumours,
disappears with increasing tumour size (Sugarbaker
et al., 1971) and, in contrast to non-metastasizing
tumours (Kearney & Nelson, 1973), may be only
transient in metastasizing tumour models (Finlay-
Jones et al., 1980).
Antitumour immune responses may be sup-
pressed by a variety of tumour-associated factors
including tumour-bearer serum (Bartholomaeus
et al., 1974), solubilized tumour cell components
(Minami et al., 1979) and tumour cell culture
supernatants (Hellstrom & Hellstr6m, 1979).
Extensive antigen shedding in vitro has been
correlated with metastatic propensity in vivo (Currie
& Alexander, 1974) and depression of macrophage
activity in vivo, the latter resulting in enhanced
tumour growth (Pike & Snyderman, 1976).
Intravenous transfer of lymphoreticular cells from
tumour-bearing animals can enhance tumour
growth in immune animals simultaneously receiving
tumour cells (Fujimoto et al., 1975) and can
suppress the antitumour activity of transferred
immune cells (Mills & North, 1983). Splenic
suppressor cell activity appeared early in these
tumour-bearing mice: Day 7 (Fujimoto et al., 1975)
and Day 9 (North & Bursuker, 1984) after tumour
inoculation. Similar results using Winn assays were
obtained in another tumour system (Carter et al.,
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1983). Spleen cells from mice bearing the
metastasizing Lewis lung carcinoma enhanced
tumour growth in recipient mice but in contrast to
the results above, this activity did not occur until
late in tumour growth, after Day 18 (Treves et al.,
1976).
We are investigating anti-tumour immune
responses and their association with metastasis,
using a methylcholanthrene-induced mouse fibro-
sarcoma designated MC-2. This tumour induces
transient CTI in the syngeneic host, with CTI
disappearing prior to the appearance of metastases
in lymph nodes regional to s.c. inoculation sites
(Finlay-Jones et al., 1980). The MC-2 tumour
produces significantly larger metastases in
immunosuppressed hosts (Finlay-Jones et al., 1980).
In this paper we describe the use of the Winn
assay (Winn, 1961) to study the development and
later suppression of splenic T cell-mediated
immunity in animals inoculated with the MC-2
tumour. Anti-tumour activity was restored to the
spleens of late-stage tumour-bearers by sublethal
whole body irradiation of the donor animals.
Materials and methods
Animals
Inbred, age-matched, female BALB/c mice were
used in all experiments. Host animals used in the
Winn assays were 2-12 months old. Blood for
serum complement was obtained by cardiac
puncture from outbred male guinea pigs of 300-
600g body weight. All animals were supplied by the
Department of Agriculture, South Australia.
Tumour
The metastasizing MC-2 fibrosarcoma which is
syngeneic for BALB/c mice has been described
previously (Finlay-Jones et al., 1980). The tumour
was maintained in vivo by serial passage every 3
weeks. Single cell suspensions were prepared from
tumour tissue by a combination of mechanical and
enzymatic disaggregation (Sheridan & Finlay-Jones,
1977). Tumour cells used in Winn assays were
grown in vitro in RPMI 1640 supplemented with
10% foetal calf serum and harvested with a 0.25%
solution of hog pancreatin (Grade VI, Sigma, Mo.,
USA). New in vitro cultures were established from
in vivo tumours at each passage. In the experiments
described the tumour had been passaged 20-40
times in vivo. A dose of 105 MC-2 cells was lethally
tumorigenic in 100% of mice.
Immunization
Mice were inoculated with 105 MC-2 cells s.c. on
the ventral surface. Five to eight days later tumours
of 30-90mg weight were excised under pento-
barbitone sodium (Nembutal, Abbott Labs.,
Sydney, Australia) anaesthesia. These mice were
rechallenged s.c. with 105 MC-2 cells 2-4 weeks
later. In some experiments immunized mice were
given a further challenge dose of 105 MC-2 cells
several months later. Mice rejecting challenge
tumours were used as donors of immune spleen
cells.
Winn assay (Winn, 1961)
Spleen cells from excision-immunized or tumour-
bearing mice were mixed with MC-2 cells and
inoculated s.c. into sublethally irradiated recipients
at a final dose of 106 spleen cells: 104 tumour
cells/mouse. MC-2 cells were harvested from short-
term tissue cultures. Spleen cells from age and sex-
matched normal mice were assayed concurrently.
As an additional control mice were also inoculated
with 104 MC-2 cells only. Each experimental group
consisted of 7-15 mice. In the experiment reported
in Table III spleen cells from immune, normal and
advanced-stage tumour-bearing mice were mixed
together in various ratios immediately before
addition to the tumour cell inoculum.
Assessment of treatment
Recipient mice were assessed for tumour incidence,
primary tumour growth rate, primary site tumour
and regional lymph node (axillary and inguinal)
weight at autopsy. Recipients were autopsied when
tumour growth was advanced, usually 20-28 days
post-inoculation. Data indicating primary tumour
incidence and size at autopsy have been presented.
Primary tumour growth rates and the extent of
lymph node metastases in Winn assay hosts
provided no additional information and have been
excluded for clarity.
Irradiation
Winn assay hosts were given 0.85Gymin-1 of
whole-body ionizing radiation 6-48 h before
inoculation. The total dose delivered was 4.0-4.5Gy
(Phillips, Holland, deep X-ray unit, 250kV, 12mA,
nil added filter, half value layer 0.7mm copper free
control, source to box distance 68cm). Early and
advanced tumour-bearers used as spleen donors
(Tables IV & V) were irradiated under the same
conditions 10 and 24 days post-inoculation
respectively. These mice were given 0.5, 2.5 or
4.0Gy and spleens were sampled 15-23h later. All
mice were irradiated in compartmented perspex
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T-cell depletion
Spleen cells were incubated for 70min at 4°C with
monoclonal anti-Thy 1.2 antibody (Ledbetter &
Herzenberg, 1979; culture supernatant from cells
obtained from the American Type Culture
Collection, Rockville, Maryland, USA, ATCC No.
TIB 107), or culture medium (RPMI 1640+10%
foetal calf serum). Cells were washed once and
incubated for 60min at 37°C with either guinea pig
serum diluted in RPMI 1640 or culture medium.
Statistics
Tumour incidences between groups were compared
using Tocher's modification of Fisher's Exact
Probability test (Siegel, 1956). Differences between
groups in the weights of primary tumours at
autopsy were compared using Student's t-test
(Armitage, 1971).
Results
Anti-MC-2 activity ofspleen cellsfrom
excision-immunized and tumour-bearing mice in vivo
is T cell-dependent
Anti-MC-2 activity in the Winn assay was detected
in spleen cells of excision-immunized (Table IA)
and early-stage tumour-bearing mice (Table iB).
This activity was depleted by pretreatment with
monoclonal anti-Thy 1.2 antibody and complement.
Immune and early-stage tumour-bearer spleen cells
treated with complement only or growth medium
Table I Anti-tumour immunity of spleen cells in Winn assay is T cell
dependent. Depletion of anti-MC-2 activity from spleen cells with anti-Thy 1.2
antibody and complement (C).
Winn assay hosts
Treatment ofdonor % Tumour Mean primary tumour
spleen cells incidencea weight+s.e. (mg)
(A)
Immune spleen
Anti-Thy 1.2+C l00b 2770+210
C only 10C 1330+
Growth medium only lOC 30+ -
Normal spleen
Anti-Thy 1.2+C 90 1780+320
C only 100 2240+280
Growth medium only 100 2160+210
No spleen cells 100 2280+ 180
(B)
Day 10 tumour-bearer spleend
Anti-Thy 1.2+C 100 1590+ 110
Growth medium only Soe 480+200
Normal spleen
Anti-Thy 1.2+C 100 1230+210
Growth medium only 100 1210+170
No spleen cells 100 1150+ 70
ai0 mice/group.
bTumour incidence significantly greater than complement or growth medium
only treatments (P<0.001, Fisher's Exact test), but not significantly different
from similarly treated normal spleen cells.
cTumour incidence significantly less than similarly treated normal spleen
cells (P<0.001, Fisher's Exact test).
dPrimary tumour weights of spleen donors were 309 and 367mg.
eSignificantly lower tumour incidence than T cell-depleted tumour-bearer
spleen group, normal spleen groups and tumour cells only group (P<0.05,
Fisher's Exact test). Of those mice developing tumours, mean primary tumour
weights significantly less than all control groups (P<0.02, Student's t-test).536 L.A. DENT & J.J. FINLAY-JONES
Table II Development and subsequent loss of detectable anti-tumour
immunity in the spleens of mice with increasing tumour burden
% TUmour
Donor incidencea,b
Days post- primary
inoculation tumour Tumour Statistical
ofspleen Exp. weight bearer Normal signifi-
donors No. (mg) spleen spleen cancec
3 1 5 82 73
6 1 25 10 100 P=0.001
2 21 20 80 P<0.025
13 1 560 40 100 P<0.005
2 610 20 100 P<0.005
20 1 2680 100 100
2 2830 100 100
27 1 5860 100 40
2 6560 78 100
'9-16 mice/group.
b104 MC-2 only inocula also tested for each day/experiment: each produced
100% incidence.
cFisher's exact test oftumour-bearer vs normal spleen cell group incidences.
only, conferred statistically significant protection
(reduced tumour incidence and tumour weight at
autopsy), when compared to recipients of antibody
plus complement-treated immune and tumour-
bearer spleen cells, normal spleen cells regardless of
treatment, and control mice receiving MC-2 cells
only.
Development and subsequent loss ofdetectable
anti-tumour immunity in vivo in mice with increasing
tumour burden
Immunity detectable in the Winn assay first
appeared in the spleens of host animals
approximately 6 days after inoculation of MC-2,
and remained statistically significant for another 7
days (Table II). In other experiments (data not
shown) weak antitumour activity has been detected
in spleens of animals up to 23 days post inoculation
of MC-2.
In one of the two experiments reported in Table
II a dose of 107 spleen cells from Day 27 tumour-
bearers produced tumours in 3/3 immunosuppressed
(4.5Gy whole-body X-irradiation) recipients.
Splenic metastases were not detected in bioassays
of other late-stage tumour-bearer spleen cell
preparations used in the experiments described
below.
Suppression ofimmune spleen cell activity by spleen
cellsfrom mice with large tumours
Since significant anti-tumour activity was generally
absent from the spleens of mice with large tumours,
experiments were performed to establish whether
the immune response was modulated by the
development of a suppressor cell population. Spleen
cells from mice with large tumours were mixed with
spleen cells from excision-immunized mice
immediately prior to combination with MC-2 cells.
In some cases spleen cells from normal mice were
also added to this mixture (as indicated) to ensure
that the total number of spleen cells inoculated into
hosts was constant.
It can be seen in Table III that a mixture of
immune and normal spleen cells (Group A)
produced total protection against an otherwise
100% tumorigenic dose of MC-2 cells (Group G).
In contrast, a mixture of late-stage tumour-bearer
and normal spleen cells (Group B) was not
protective. When 2.5x 105, 5 x 105 or 5 x 106
tumour-bearer spleen cells (Groups C, D and E
respectively) were added to an otherwise protective
dose of 5 x 105 immune spleen cells (Group A) the
protective response was significantly diminished.
Splenic metastases were not detected in the late-
stage tumour-bearer spleen cells when they were
bioassayed in immunosuppressed mice.
This experiment has been repeated a number of
times with similar results. Two variables were
deemed critical to the demonstration of
suppression: (i) a large tumour burden in the donor
animal and (ii) the ratio of tumour-bearer spleen
cells to immune cells, with the lower ratios showing
marginally more suppression.IMMUNITY TO A METASTASIZING FIBROSARCOMA 537
Table III Suppression of immune spleen cell activity in the Winn assay by addition of
spleen cells from mice with large tumoursa
Winn assay hosts
Mean
r _ primary
Tumour- tumour
Group 105 x bearer :Normal :Immune :104 % Tumour weight
spleen spleen spleen MC-2b incidencec +s.e. (mg)
A 0 5 5 od
B 5 5 0 90 2380+340
C 2.5 2.5 5 70 2510+340e
D 5 0 5 56 2220+300
E 50 0 5 40 1460+ 190e
F 50 5 0 100 1740+300e
G 0 0 0 100 2380+160
aAdvanced tumour-bearer spleens sampled 22 days after MC-2 tumour inoculation.
Primary tumour weights of spleen donors 3293, 3924mg.
bSpleen cells from late-stage tumour-bearer, normal and excision immunized mice mixed in
various ratios to final concentrations of 106 spleens cells/mouse. Spleen cells were then mixed
with a 100% tumourigenic dose of 104 MC-2 cells and inoculated into Winn assay host
animals.
C9 10 mice/group.
dSignificantly lower tumour incidence than all other groups (0.0001 <P<0.05, Fisher's
Exact test) i.e. significant suppression of protective response when tumour-bearer spleen cells
added.
eGroup E vs Group G, P<0.001; Group F vs Group G, P<0.01; Group C vs Group E,
P<0.05; Student's t-test.
Protective activity restored to spleens ofmice with
large tumoursfollowing whole-body irradiation
Animals with large primary tumours were given
doses of 0.5, 2.5 or 4.0Gy whole-body X-
irradiation 15h prior to spleen sampling. Spleen
cells from unirradiated mice with tumours of
similar size were not protective in the Winn assay
(Table IV).
Tumour incidence was significantly less in the
0.5Gy- and 2.5 Gy-treated tumour-bearer spleen
donor groups than that seen in groups receiving
tumour cells only, or tumour cells mixed with
spleen cells from normal or irradiated naive mice,
or unirradiated tumour-bearers. Primary tumours
which developed in Winn assay host mice receiving
spleen cells from 2.5 Gy treated tumour-bearing
animals were also significantly smaller at autopsy
than those in the various control treatment groups.
Protective activity was reduced to statistically
insignificant levels in spleen cells from late-stage
tumour-bearers pretreated with the highest dose of
radiation (4.0Gy).
Radiosensitivity ofprotective splenic effector cells
from early-stage tumour-bearing donor mice
Doses of 1.5 and 2.5 Gy of whole-body X-
irradiation 23 h prior to spleen sampling did not
reduce protective activity conferred by spleen cells
from mice with small tumours (Table V). Anti-
tumour effector cells were partially susceptible to
4.0Gy of whole-body irradiation. Tumour incidence
in mice receiving spleen cells from 4.0Gy-pretreated
early-stage tumour-bearing donors was not
significantly different from the control group
receiving MC-2 cells only. However, the autopsy
weights of primary-site tumours of the former
group were significantly less than those in the
control group, indicating some residual protective
activity.
Discussion
In investigating factors influencing the metastasis of
a murine fibrosarcoma, we (Finlay-Jones et al.,538 L.A. DENT & J.J. FINLAY-JONES
Table IV Whole-body irradiation restores protective
activity to spleen cells of advanced-stage tumour-bearing
donor mice
Winn assay hosts
Treatment of Mean primary
spleen donorsa % Tumour tumour weight at
(Gy) incidenceb autopsy ±s.e. (mg)
Normal 0 100 2720+200
Normal 4.0 100 2790+300
Tumour-bearer 0 100 2630+110
Tumour-bearer 0.5 60C 2240+410
Tumour-bearer 2.5 50c 690+260d
Tumour-bearer 4.0 70 2140+490
No spleen cells 100 2780+310
aTumour-bearers irradiated 24 days after inoculation
with 105 MC-2 cells, spleens sampled 15h later. Primary
tumour weights (mg) of spleen donors were 3250, 5338
(OGy); 3568, 3892 (0.5Gy); 4132 (2.5Gy); 4432, 4465
(4.0Gy).
"10 mice/group, except Normal 4.0Gy:5 mice.
cMore protective than spleens from unirradiated normal
and tumour-bearing mice (P<0.05, Fisher Exact test).
dSignificantly lower mean primary tumour weight at
autopsy than all other groups P<0.02 (Student's t-test).
1980) have found several associations between
antitumour immunity and metastasis. Firstly, the
MC-2 fibrosarcoma induces transient CTI in the
syngeneic host, with CTI developing then
disappearing prior to the growth of metastases.
Secondly, metastasis of MC-2 is enhanced in
immunosuppressed hosts. We have also found that
tissue-culture-derived sublines with reduced metas-
tatic propensity induce a prolonged CTI and show
increased metastasis in immunosuppressed hosts
(Finlay-Jones & Dent, in preparation). With the use
of the Winn assay, we have documented in this
paper the acquisition then loss of T-lymphocyte
dependent immunity in spleens of tumour-bearing
hosts, and present evidence which suggests that this
modulation was due to splenic suppressor cells.
In vivo immunity to the metastasizing murine
fibrosarcoma MC-2 was dependent on T cells
(Table I). Spleen cells from normal animals usually
showed little protective activity. Similar findings
using Winn assays have been reported for other
chemically-induced, but non-metastasizing sarcomas
(Shimizu & Shen, 1979; Carter et al., 1983).
Anti-tumour immunity as detected in the Winn
assay emerged in, and was then lost from spleens of
tumour-bearing animals (Table II). As with CTI
(Finlay-Jones et al., 1980), immunity detectable in
the Winn assay first appeared in the spleens of host
animals approximately 6 days after inoculation of
MC-2. However, in contrast to CTI, statistically
significant protection was detectable in the Winn
Table V Radiosensitivity of protective splenic effector
cells from early-stage tumour-bearing donor mice
Winn assay hosts
Mean primary
Treatment of tumour weight
spleen donors % Tumour autopsy±s.e. (mg)
(Gy)a incidenceb (mg)
Tumour-bearer 0 20C 860+450
Tumour-bearer 1.5 22C 850+290
Tumour-bearer 2.5 27c 470+430
Tumour-bearer 4.0 80 670+ 150d
No spleen cells 90 1370+ 180
aTumour-bearers irradiated 10 days after inoculation
with I05 MC-2 cells, spleens sampled 23h later.
Primary tumour weights (mg) of spleen donors were
365, 365 (OGy); 247, 421 (1.5Gy); 290, 393 (2.5Gy); 250,
420 (4.0Gy).
b91_1 mice/group.
CSignificantly lower tumour incidence than mice
receiving 104 MC-2 cells only (0.005<P<0.01, Fisher
Exact test).
dPrimary tumour weights at autopsy significantly less
than those of mice given 104 MC-2 cells only (P=0.005,
Student's t-test).
assay for at least another 7 days (Table II).
Significant protection was detectable in the spleens
of animals with primary tumour burdens of
>500mg, whereas CTI in this model could only be
demonstrated over an approximate tumour weight
range of 5-80mg (Finlay-Jones et al., 1980). In
separate experiments (not shown) partial protection
was present up to 23 days after inoculation of MC-
2 into spleen donors. However, the Winn assay has
been used in this model to test systemic (splenic)
immunity, whereas CTI may reflect local immunity
(i.e. regional lymph node immunity). It should be
noted that in both cases anti-tumour activity
disappeared from animals as their tumour burden
increased.
Artificial increases in tumour load produced by
injection of soluble tumour antigens (Gatenby et
al., 1981) or irradiated tumour cells (Hellstrom &
Hellstr6m, 1978; North, 1982) induce cell
populations capable of suppressing anti-tumour
immune responses. In the MC-2 model, loss of
protective activity from spleens of mice with large
primary tumours and metastases, was coincident
with the development in vivo of suppressive activity
against otherwise protective immune spleen cells
(Table III). Others have reported the development
of a suppressor cell population in the spleens of
tumour-bearing mice but, in contrast to our
findings, this appeared early (Days 7-9) in tumour
growth (Fujimoto et al., 1975; Carter et al., 1983;
North & Bursuker, 1984). In contrast, Treves et al.IMMUNITY TO A METASTASIZING FIBROSARCOMA
(1976) described tumour-enhancing cells developing
in spleens of mice late (Day 19+) in the growth of
the metastasizing Lewis lung carcinoma. It may be
that differences in assays used could account for the
differences in kinetics. However, the ratios of
tumour cells to spleen cells (immune and
suppressor) used in our experiments were similar to
those of Carter et al. (1983). An alternative
possibility is that the differences in kinetics may
relate to biological differences in the tumour
systems used. The metastatic propensities of the
tumour models may influence the type of
suppressor cells arising and the timing of their
expression.
The eventual loss of immunity and development
of suppressor cell activity in the spleens of late-
stage MC-2 bearing mice may be associated with
onset of metastases in the spleens of some mice,
and may reflect a similar process occurring much
earlier in lymph nodes draining the primary tumour
inoculation site. Such a process may then facilitate
the development of lymph node metastases which
are histologically observable only 8 days after s.c.
inoculation of MC-2 (Finlay-Jones et al., 1980).
The immune responsiveness of lymph node cells
from mice with MC-2 tumours, and its relationship
to the appearance of lymph node metastases, is
currently under investigation.
Information concerning the nature of the
suppressor cells was obtained in experiments in
which sublethal whole-body irradiation of mice
with large tumours restored anti-tumour protective
activity to their spleens (Table IV). In contrast,
anti-tumour effector cells present in the spleens of
mice with small tumours were resistant to 2.5Gy or
less of whole-body irradiation (Table V). Residual
protective activity was also detected in the spleens
of early-stage tumour-bearing mice given 4.0Gy of
whole-body irradiation. It would seem that the
radiation-induced restoration of protection to the
spleens of mice with large tumours (Table IV), was
due either to a direct stimulatory influence on
inactive effector cells, or elimination of a cell
subpopulation modulating effector cell activity.
However, the former is unlikely in that the activity
of effector cells was not directly enhanced by low
dose irradiation (Table V).
The activity of suppressor cells can be ablated
experimentally using immunosuppressive treatments
which appear to leave cytotoxic T cell activity,
mitogen responsiveness and delayed-type hyper-
sensitivity intact (Rollinghoff et al., 1977; Glaser,
1979; Minami et al., 1979; North, 1982). Suppressor
T cells are known to be more radiosensitive than
other T cell subpopulations (Basten et al., 1975;
Dutton, 1975) and this is thought to explain
observed augmentation of immune responses
following low-dose ionizing radiation (Anderson et
al., 1981; Doria et al., 1982). Radiation may also
enhance antigen processing by macrophages,
leaving their phagocytic and migratory behaviour
intact (Anderson & Warner, 1976).
Sublethal whole-body irradiation of mice with
small tumours can reduce tumour incidence or size
(Hellstrom et al., 1978). This effect can be
duplicated by radiation restricted to the spleen
region (Enker & Jacobitz, 1980) and is probably
due to elimination of suppressor T cells, since
reconstitution with T cell-enriched normal spleen
cells soon after irradiation can result in tumour
growth comparable with that in unirradiated
controls (Hellstrom et al., 1978). It is possible that
irradiation of tumour-bearers early in tumour
development has direct cytocidal activity on the
tumour. Radiation-induced gut damage may reduce
the nutritional status of the host and therefore
indirectly inhibit tumour growth. Leakage of gut
contents may also serve to non-specifically
stimulate the host's immune system. Artificial lung
metastases may be reduced by high dose (12.0Gy)
irradiation of recipient gut tissue a week prior to
i.v. tumour challenge (Ando et al., 1980). Some of
these technical drawbacks concerning the use of
irradiation in directly affecting cells of the immune
system have been overcome in the experiments
reported in Tables IV and V.
Splenic metastases are occasionally found in mice
bearing late-stage MC-2 tumours. However,
suppression detected by mixing tumour-bearer and
immune spleen cells in the Winn assay was
probably not due to simple addition of putative
splenic tumour metastases to the tumour load.
Tumours did not arise in bioassays of the tumour-
bearer spleen cells which showed suppression.
Further, the radiosensitivity of the suppressor cells
is at variance with the relative radioresistance of
MC-2 tumour cells (Dent & Finlay-Jones,
unpublished observations).
Development of suppressor cell activity and loss
of protection may be reversed by manipulation of
the cellular immune response. An understanding of
the changes in cellular immune responses, and
the potential for manipulating them, for example
with low doses of radiation, may lead to more
effective cancer therapy.
The authors wish to thank Drs D. Horsfall and W. Tilley
for the guinea pig blood. Irradiation was performed with
the cooperation of Dr D. Wigg and the kind assistance of
his staff at the Radiotherapy Department, Royal Adelaide
Hospital, South Australia. We gratefully acknowledge the
contributions of Mrs Wendy Graham and Miss Judy
Stone for typing, Dr Frances Noonan for valuable
discussion of the manuscript and Ms Gaby Kriek for
technical assistance. This work was financially supported
by project grants from the National Health and Medical
Research Council of Australia. L.A. Dent was assisted by
a Commonwealth of Australia Postgraduate Research
Award.
539540 L.A. DENT & J.J. FINLAY-JONES
References
ANDERSON, R.E., LEFKOVITS, I. & TROUP, G.M. (1981).
Radiation-induced augmentation of the immune
response. Contemp. Top. Immunobiol., 11, 245.
ANDERSON, R.E. & WARNER, N.L. (1976). Ionizing
radiation and the immune response. Adv. Immunol.,
24, 215.
ANDO, K., HUNTER, N. & PETERS, L.J. (1980). Inhibition
of artificial lung metastases in mice by preirradiation
of abdomen. Br. J. Cancer, 41, 250.
ARMITAGE, P. (1971). Statistical Methods in Medical
Research, Blackwell Sci. Publ., Oxford.
BARTHOLOMAEUS, W.N., BRAY, A.E., PAPADIMITRIOU,
J.M. & KEAST, D. (1974). Immune response to a
transplantable malignant melanoma in mice. J. Nati
Cancer Inst., 53, 1065.
BASTEN, A., MILLER, J.F.A.P. & JOHNSON, P. (1975). T
cell-dependent suppression of an anti-hapten antibody
response. Transplant. Rev., 26, 130.
CARTER, R.H., DREBIN, J.A., SCHATTEN, S., PERRY, L.L.
& GREENE, M.I. (1983). Regulation of the immune
response to tumor antigens. IX. In vitro Lyt-1 2-
cell proliferative responses to cell bound or subcellular
tumor antigen. J. Immunol., 130, 997.
CURRIE, G.A. & ALEXANDER, P. (1974). Spontaneous
shedding of TSTA by viable sarcoma cells: its possible
role in facilitating metastatic spread. Br. J. Cancer, 29,
72.
DE VITA, V.T., YOUNG, R.C. & CANELLOS, G.P. (1975).
Combination versus single agent chemotherapy: a
review of the basis for selection of drug treatment of
cancer. Cancer, 35, 98.
DORIA, G., AGAROSSI, G. & ADORINI, L. (1982). Selective
effects of ionizing radiations on immunoregulatory
cells. Immunol. Rev., 65, 23.
DUTTON, R.W. (1975). Suppressor T cells. Transplant.
Rev., 26, 40.
ECCLES, S.A. & ALEXANDER, P. (1974). Macrophage
content of tumours in relation to metastatic spread
and host immune reaction. Nature, 250, 667.
ENKER, W.E. & JACOBITZ, J.L. (1980). In vivo splenic
irradiation eradicates suppressor T-cells causing the
regression and inhibition of established tumor. Int. J.
Cancer, 25, 819.
FINLAY-JONES, J.J., BARTHOLOMAEUS, W.N., FIMMEL,
P.J., KEAST, D. & STANLEY, N.F. (1980). Biologic and
immunologic studies on a murine model of regional
lymph node metastasis. J. Natl Cancer;Inst., 64, 1363.
FLANNERY, G.R., CHALMERS, P.J., ROLLAND, J.M. &
NAIRN, R.C. (1973). Immune response to a syngeneic
rat tumour: evolution of serum cytotoxicity and
blockade. Br. J. Cancer, 28, 293.
FUJIMOTO, S., GREENE, M. & SEHON, A.H. (1975).
Immunosuppressor T cells in tumor bearing hosts.
Immunol. Commun., 4, 201.
GERSHON, R.K. (1974). Concomitant tumor immunity. In:
Interaction of Radiation and Host Immune Defense
Mechanisms in Malignancy, p. 52, (ed Bond et al.),
Brookhaven National Lab.: Springfield, Virginia.
GATENBY, P.A., BASTEN, A. & CRESWICK, P. (1981).
"Sneaking through": a T-cell-dependent phenomenon.
Br. J. Cancer, 44, 753.
GLASER, M. (1979). Regulation of specific cell-mediated
cytotoxic response against SV40-induced tumor
associated antigens by depletion of suppressor T cells
with cyclophosphamide in mice. J. Exp. Med, 149,
774.
HAMLIN, I.M.E. (1968). Possible host resistance in
carcinoma of the breast: a histological study. Br. J.
Cancer, 23, 366.
HELLSTROM, K.E. & HELLSTROM, I. (1979).
Enhancement of tumur outgrowth by tumor-associated
blocking factors. Int. J. Cancer, 22, 383.
HELLSTROM, K.E. & HELLSTROM, I. (1978). Evidence
that tumour antigens enhance tumour growth in vivo
by interacting with a radiosensitive (suppressor?) cell
population. Proc. Natl Acad. Sci., 75, 436.
HELLSTROM, K.E., HELLSTROM, I., KANT, J.A. &
TAMERIUS, J.D. (1978). Regression and inhibition of
sarcoma growth by interference with a radio-sensitive
T-cell population. J. Exp. Med., 148, 799.
KEARNEY, R. & NELSON, D.S. (1973). Concomitant
immunity to syngeneic methylcholanthrene-induced
tumours in mice. Occurrence and specificity of
concomitant immunity. Aust. J. Exp. Biol. Med. Sci.,
51, 723.
LEDBETTER, J.A. & HERZENBERG, L.A. (1979).
Xenogeneic monoclonal antibodies to mouse lymphoid
differentiation antigens. Immunol. Rev., 47, 63.
MILLS, C.D. & NORTH, R.J. (1983). Expression of passively
transferred immunity against an established tumor
depends on generation of cytolytic T cells in recipient.
Inhibition by suppressor T cells. J. Exp. Med., 157,
1448.
MINAMI, A., MIZUSHIMA, Y., TAKEICHI, N.,
HOSOKAWA, M. & KOBAYASHI, H. (1979).
Dissociation of anti-tumor immune responses in rats
immunized with solubilized tumor-associated antigens
from a methylcholanthrene-induced fibrosarcoma. Int.
J. Cancer, 23, 358.
NORTH, R.J. (1982). Cyclophosphamide-facilitated
adoptive immunotherapy of an established tumor
depends on elimination of tumor-induced suppressor
cells. J. Exp. Med., 155, 1063.
NORTH, R.J. & BURSUKER, I. (1984). Generation and
decay of the immune response to a progressive
fibrosarcoma. I. Ly- +2- suppressor T cells down-
regulate the generation of Ly-1-2+ effector T cells. J.
Exp. Med., 159, 1295.
PIKE, M.C. & SNYDERMAN, R. (1976). Depression of
macrophage function by a factor produced by
neoplasms: a mechanism for abrogation of immune
surveillance. J. Immunol., 117, 1243.
ROLLINGHOFF, M., STARZINSKI-POWITZ, A.,
PFIZENMAIER, K. & WAGNER, H. (1977). Cyclophos-
phamide-sensitive T lymphocytes suppress the in vivo
generation of antigen-specific cytoxic T lymphocytes.
J. Exp. Med., 145, 455.
ROOS, E. & DINGEMANS, K.P. (1979). Mechanisms of
metastasis. Biochim. Biophys. Acta, 560, 135.IMMUNITY TO A METASTASIZING FIBROSARCOMA 541
SHERIDAN, J.W. & FINLAY-JONES, J.J. (1977). Studies on
a fractionated murine fibrosarcoma: A reproducible
method for the cautious and a caution for the unwary.
J. Cell. Physiol, 90, 535.
SHIMIZU, K. & SHEN, F.W. (1979). Role of different T cell
sets in the rejection of syngeneic chemically induced
tumors. J. Immunol., 122, 1162.
SIEGEL, S. (1956). Nonparametric Statistics for the
Behavioral Sciences, McGraw-Hill Kogakusha: Tokyo.
SUGARBAKER, E.V., COHEN, A.M. & KETCHAM, A.S.
(1971). Concomitant tumor immunity and
immunoselection of metastases. Currt. Top. Surg. Res.,
3, 349.
TALMADGE, J.E., KEY, M. & FIDLER, I.J. (1981).
Macrophage content of metastatic and nonmetastatic
rodent neoplasms. J. Immunol., 126, 2245.
TREVES, A.J., COHEN, I.R. & FELDMAN, M. (1976). A
syngeneic metastatic tumor model in mice: the natural
immune response of the host and its manipulation. In:
Immunological Parameters of Host-Tumor Relation-
ships, Vol. IV, p. 89 (ed. Weiss) Academic Press:
New York.
WINN, H.J. (1961). Immune mechanisms in homotrans-
plantation. II. Quantitative assay of the immunologic
activity of lymphoid cells stimulated by tumor homo-
grafts. J. Immunol., 86, 228.